ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
ZyVersa Therapeutics Inc

ZyVersa Therapeutics Inc (ZVSA)

0.6355
0.00
(0.00%)
Closed April 16 4:00PM
0.00
0.00
(0.00%)

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.6355
Bid
0.6355
Ask
0.6498
Volume
-
0.00 Day's Range 0.00
0.50 52 Week Range 90.65
Market Cap
Previous Close
0.6355
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
2,646,952
Shares Outstanding
1,243,297
Dividend Yield
-
PE Ratio
-0.26
Earnings Per Share (EPS)
-85.46
Revenue
-
Net Profit
-106.25M

About ZyVersa Therapeutics Inc

ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medi... ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medical needs, with emphasis on inflammatory and renal diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Website
Headquarters
Wilmington, Delaware, USA
Founded
2022
ZyVersa Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZVSA. The last closing price for ZyVersa Therapeutics was $0.64. Over the last year, ZyVersa Therapeutics shares have traded in a share price range of $ 0.50 to $ 90.65.

ZyVersa Therapeutics currently has 1,243,297 shares outstanding. The market capitalization of ZyVersa Therapeutics is $27.97 million. ZyVersa Therapeutics has a price to earnings ratio (PE ratio) of -0.26.

ZVSA Latest News

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published...

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical...

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys’ filtration...

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.ZyVersa is...

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate...

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

Obesity, which affects over 1.9 billion people worldwide, is a state of low-grade chronic inflammation that causes an array of different metabolic disorders, including insulin resistance, type 2...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0845-11.73611111110.720.80460.632981190.70298199CS
4-0.1886-22.88557213930.82410.8710.633804520.75474885CS
120.02854.695222405270.6072.50.5426469520.9939586CS
26-3.792-85.64652738574.42754.7250.529921831.96993718CS
52-60.9645-98.968344155861.690.650.534847985.72531926CS
156-489.3645-99.8703061224490523.250.526939908.90123776CS
260-489.3645-99.8703061224490523.250.526939908.90123776CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.4174
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.04
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.90
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.2801
(0.00%)
0
AACGATA Creativity Global
$ 0.86
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.4174
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.04
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.90
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.2801
(0.00%)
0
AACGATA Creativity Global
$ 0.86
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.4174
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.04
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.90
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.2801
(0.00%)
0
AACGATA Creativity Global
$ 0.86
(0.00%)
0

ZVSA Discussion

View Posts
Awl416 Awl416 4 weeks ago
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
👍️0
surf1944 surf1944 1 month ago
Closed the .80 gap buying back into ZVSA on weakness.
👍️0
surf1944 surf1944 2 months ago
https://stockcharts.com/h-sc/ui?s=zvsa&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/zvsa/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/zvsa/opinion

https://finance.yahoo.com/quote/ZVSA/key-statistics

Open gap at .80
👍️0
IoT II IoT II 2 months ago
Goodmorning


https://stocktwits.com/3227blake/message/563183532

$$$ZVSA$$$
👍️0
Invest-in-America Invest-in-America 2 months ago
ZVSA: Un-plugged it from halt!!!
👍️0
Invest-in-America Invest-in-America 2 months ago
ZVSA: Just a science "WHITE PAPER" does this??? And from DAYS AGO???
👍️0
Invest-in-America Invest-in-America 2 months ago
ZVSA: Let's get ready to RUMMMMMMMMMM-BULL!!!!!

👍️0
dirtydozen911 dirtydozen911 2 months ago
RUNNER ON MONDAY

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
👍️0
glenn1919 glenn1919 2 months ago
ZVSA..................................https://stockcharts.com/h-sc/ui?s=ZVSA&p=W&b=5&g=0&id=p86431144783
👍️0
da_stock_analyst da_stock_analyst 2 months ago
#ZVSA 🔥 big move next week? Low float, huge upside? $ZVSA
👍️0
dirtydozen911 dirtydozen911 2 months ago
Started move around 3 30

Strong in a h
Set up to run Monday.

$$$$ ??? $$$
👍️0
Monksdream Monksdream 3 months ago
ZVSA new 52 week low
👍️0
GhosTraderX GhosTraderX 4 months ago
$ZVSA$ Nice move today...

Bought in at 0.925 ish

GhosT
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
ZVSA READY TO BREAK A NEW HIGH
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
LOW VOLUME COMBUSTION
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
ZVSA...ON THE MOVE POST SPLIT
👍️0
Monksdream Monksdream 4 months ago
ZVSA new 52 week low
👍️0
Monksdream Monksdream 4 months ago
ZVSA new 52 week low
👍️0
TheFinalCD TheFinalCD 4 months ago
$ZVSA NEWS , POST 1-35 RS DEC 4

https://finviz.com/quote.ashx?t=ZVSA&ty=c&ta=1&p=d

NOV S-1 IN PROGESS
https://ih.advfn.com/stock-market/NASDAQ/zyversa-therapeutics-ZVSA/stock-news/92612528/form-424b3-prospectus-rule-424b3
https://dilutiontracker.com/app/search/ZVSA
👍️0
tw0122 tw0122 5 months ago
ZVSA Boomtime up 72% quickly .11
👍️0
subslover subslover 5 months ago
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract affecting 1 in 100 Americans (around 2.4 million people) that can lead to disabling bowel symptoms and progressive bowel damage.
Study provides direct evidence that NLRP3 signaling is over-activated in IBD, and that its inhibition attenuates intestinal inflammation and tissue damage, leading to significant improvements in IBD symptoms, and restoration of normal intestinal microbial flora.
ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.
WESTON, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed Biomedical Journal demonstrating that inhibiting NLRP3 inflammasomes in an IBD animal model attenuates intestinal inflammation and tissue damage, leading to significant improvements in IBD symptoms, and restoration of normal intestinal microbial flora.

In the paper titled, “Inhibition of NLRP3 attenuates sodium dextran sulfate-induced inflammatory bowel disease through gut microbiota regulation,” the authors evaluated human colon biopsy samples from patients with IBD and healthy controls, and conducted a study in an IBD mouse model. Following are key findings reported in the paper:

NLRP3 and IL-1ß expression is increased in the colon of IBD patients.
NLRP3 inhibition in the IBD animal model: Inhibited NLRP3 inflammasome signaling in the colon, resulting in significantly reduced levels of the pro-inflammatory cytokines IL-1b, IL-6, and TNF-a.Alleviated severe diarrhea and significantly improved IBD symptoms, based on the disease activity index score.Attenuated histopathological changes indicative of tissue damage (goblet cell reduction, crypt destruction, and epithelial barrier disruption).Restored gut microbiota to normal.
The authors stated, “In conclusion, this study provides direct evidence that NLRP3 signaling is over-activated in IBD patients. The inhibition of NLRP3 reverses the IBD-like symptoms in DSS-induced mice, which the regulatory effects on gut microbiota might mediate. Overall, this present study provides a basis for the clinical application of NLRP3 as a target for IBD treatment.” To read the article, Click Here.

“Restoration of quality of life is the ultimate long-term goal in IBD management. Although disease remission can often be achieved with current therapies, bothersome symptoms can still prevail,” stated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President. “The research published in the Biomedical Journal provides support for inflammasome inhibition as a promising treatment option for IBD. ZyVersa is developing Inflammasome ASC inhibitor IC 100. Unlike NLRP3 inhibitors, designed to inhibit formation of one inflammasome to block initiation of the inflammatory cascade, IC 100 was designed to inhibit multiple types of inflammasomes and their associated ASC specks to uniquely block both initiation and perpetuation of damaging inflammation, which we believe is necessary to control chronic inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here.

About Inflammasome ASC Inhibitor IC 100

IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1ß early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1ß and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response.

About ZyVersa Therapeutics, Inc.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa’s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa’s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa’s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa’s plans to research, develop, and commercialize its current and future product
👍️0
CashCowMoo CashCowMoo 5 months ago
ZVSA pump failed for the buyers.
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
fake traders never get it right
👍️0
Triple nickle Triple nickle 5 months ago
Here comes the momo
👍️0
INFINITI INFINITI 5 months ago
Zvsa 😀
👍️0
Awl416 Awl416 5 months ago
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuro
👍️0
CashCowMoo CashCowMoo 6 months ago
Keep buying. The losers of the biopharma pump and dump are loving your buys.
👍️0
0whammies 0whammies 6 months ago
me 2
👍️0
CashCowMoo CashCowMoo 7 months ago
Yeah I made the mistake of buying into this one on the pump over the summer that was going on. It has crashed ever since.
👍️0
trendzone trendzone 7 months ago
Most Micro stocks are and act like garbage 80% of the time, there only swing trades or day trades, unless there is some really big news that can get them, and can keep them out of the sewer, where most of them end up swimming, they are always stock offering risks,especially after quick run ups, I own it in the low $0.12, it's been getting a good amount of buyside volume in the past few days, and could be setting up for more gains.
👍️0
TrendTrade2016 TrendTrade2016 7 months ago
don't play options, but this stock is garbage...
👍️0
trendzone trendzone 7 months ago
You are not even worth answering back to, other then for the entertainment value of it, you are such a clueless fool with your comments more than 95% of the time, then again,you have allready proved that on other boards, go buy some more $SPY calls, bet that's been going real well, that is if you like accumulating red bags.
👍️0
TrendTrade2016 TrendTrade2016 7 months ago
now we know you have no clue what you are doing
👍️0
trendzone trendzone 7 months ago
It needs to break back above $0.14 again today,and close above that level, and get the manipulators that keep show size on the offer off its back,if the market wasn't down again today it could of possible took out $0.15, it could be setting up for a run to $0.18 in the short term, especially if the fools on the offer get taken out.
👍️0
trendzone trendzone 7 months ago
Yup, the 63 split window is one of the favorite and nicest looking C2 vetts, I always liked the 67 big block, mine is a 350,350 small block yellow convertible, I have had it since 1981, I am the second owner since then.
👍️0
81vette 81vette 7 months ago
Zvsa is a muscle car racing up today
👍️0
81vette 81vette 7 months ago
Gotta love the classic muscle of vettes,69 is a popular year for all muscle cars,hang on to that one,my fav is 63 split window
👍️0
trendzone trendzone 7 months ago
Going by your name,I'm guessing you own an 81 corvette,I own a 69 vette.
👍️0
trendzone trendzone 7 months ago
Definitely a brainless moron who keeps showing size on the offer, could be a real dumbass short position,trying to stop a breakout so they get squeezed,and their butts handed to them.
👍️0
81vette 81vette 7 months ago
51% win 2 Wednesdays ago,let’s see what this one does
👍️0
trendzone trendzone 7 months ago
The D bag is now showing size at $0.1545, the creeps need to get squeezed and have to cover over $0.16.
👍️0
trendzone trendzone 7 months ago
Douche bag manipulator showing zize at $0.15, probably because they haven't covered their short yet, time to squeeze the corrupt SOB.
👍️0
csud1 csud1 7 months ago
Implode is more like it
👍️0
ttottip ttottip 7 months ago
This can explode at any moment!
👍️0
INV4 INV4 7 months ago
I don't like fleas! SMH.
Thnx for posting this.
👍️0
subslover subslover 7 months ago
Oye Vay. :(
👍️0
TheFinalCD TheFinalCD 7 months ago
ANOTHER DOG WITH FLEAS https://ih.advfn.com/stock-market/NASDAQ/zyversa-therapeutics-ZVSA/stock-news/92040892/form-8-k-current-report
👍️0
INV4 INV4 7 months ago
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases

September 12 2023

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of a paper in the peer-reviewed journal, Frontiers in Immunology, highlighting potential limitations of NLRP3 inhibition in attenuating CNS Inflammation associated with activation of multiple inflammasome pathways. This paper supports ZyVersa’s rationale for targeting inflammasome ASC with IC 100 to inhibit multiple inflammasome pathways, not just NLRP3, to control inflammation in various inflammatory diseases.

In the paper titled, “Divergent functional outcomes of NLRP3 blockade downstream of multi-inflammasome activation: therapeutic implications for ALS,” the authors conducted studies in various human cell lines and in an animal model of ALS. Data demonstrate that NLRP3 inhibition alone is insufficient to attenuate proinflammatory cytokine release and inflammatory cell death associated with activation of multiple inflammasome pathways. Likewise, NLRP3 inhibition alone did not ameliorate spinal cord inflammation in an ALS model.

The authors stated, “we hypothesize that strategies that impact multiple inflammasome pathways may hold more promise in CNS disorders like ALS where multiple inflammasomes are dysregulated.” To read the article Click Here.

“The research published in Frontiers in Immunology reinforces the need to inhibit more than the NLRP3 inflammasome pathway to control inflammation associated with activation of multiple inflammasomes,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President. “ZyVersa’s Inflammasome ASC inhibitor IC 100 is designed to inhibit formation of multiple types of inflammasomes to attenuate initiation of the inflammatory cascade, and to inhibit ASC specks to attenuate perpetuation of damaging inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here.

About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1ß early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1ß and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response.

About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

https://ih.advfn.com/stock-market/NASDAQ/zyversa-therapeutics-ZVSA/stock-news/92019000/zyversa-therapeutics-announces-research-published

$ZVSA
👍️0
INV4 INV4 7 months ago
Nice!!
$ZVSA
👍️0
TrendTrade2016 TrendTrade2016 7 months ago
HERE WE GO
👍️0

Your Recent History

Delayed Upgrade Clock